Tarvacin Equivalent Plus Docetaxel Inhibits Breast Tumor Growth by 93 Percent
Peregrine Pharmaceuticals has announced that a research article titled, "A Monoclonal Antibody that Binds Anionic Phospholipids on Tumor Blood Vessels Enhances the Antitumor Effect of Docetaxel on Human Breast Tumors in Mice," was published in the May 15 issue of Cancer Research.
The published report shows that 3G4 (a murine equivalent of the company's Tarvacin monoclonal antibody) in combination with docetaxel results in a 93 percent inhibition of human breast cancer growth in mouse models. The researchers found that docetaxel increases the exposure of the 3G4 target on tumor blood vessels but not healthy tissue.
Patient enrollment in a Tarvacin Phase I clinical trial for the treatment of all solid tumors, including breast cancer, is expected to commence this month at three clinical sites.